Potential therapeutic targets for treatment of the overactive bladder

Donna J. Sellers, R. Christopher, Chappie Russell Chess-Williams

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

Muscarinic receptor antagonists remain the main therapy for the treatment of the overactive bladder yet severe adverse effects make them unsuitable for a large number of patients. The development of new drugs with novel mechanisms of action for the treatment of this condition is therefore essential. This article considers some of the targets currently under investigation for the development of such compounds. jS-adrenoceptor agonists and KATP channel openers inhibit detrusor muscle activity and remain targets for drug development. There is also evidence that a-adrenoceptor antagonists may be effective in the overactive bladder, but the mechanism involved in this action is unclear. Finally the role of tachykinins in regulating bladder function through both the sensory and the motor innervation make them a potential target for drug development, but as with the the others, a selective action on the bladder must remain the goal of drug development.

Original languageEnglish
Pages (from-to)307-311
Number of pages5
JournalWorld Journal of Urology
Volume19
Issue number5
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Overactive Urinary Bladder
Pharmaceutical Preparations
Adrenergic Receptors
Urinary Bladder
Tachykinins
KATP Channels
Muscarinic Antagonists
Muscarinic Receptors
Therapeutics
Muscles

Cite this

Sellers, Donna J. ; Christopher, R. ; Chess-Williams, Chappie Russell. / Potential therapeutic targets for treatment of the overactive bladder. In: World Journal of Urology. 2001 ; Vol. 19, No. 5. pp. 307-311.
@article{3d4b31856fc04247901c5b3ec928ac98,
title = "Potential therapeutic targets for treatment of the overactive bladder",
abstract = "Muscarinic receptor antagonists remain the main therapy for the treatment of the overactive bladder yet severe adverse effects make them unsuitable for a large number of patients. The development of new drugs with novel mechanisms of action for the treatment of this condition is therefore essential. This article considers some of the targets currently under investigation for the development of such compounds. jS-adrenoceptor agonists and KATP channel openers inhibit detrusor muscle activity and remain targets for drug development. There is also evidence that a-adrenoceptor antagonists may be effective in the overactive bladder, but the mechanism involved in this action is unclear. Finally the role of tachykinins in regulating bladder function through both the sensory and the motor innervation make them a potential target for drug development, but as with the the others, a selective action on the bladder must remain the goal of drug development.",
author = "Sellers, {Donna J.} and R. Christopher and Chess-Williams, {Chappie Russell}",
year = "2001",
doi = "10.1517/14728222.8.2.95",
language = "English",
volume = "19",
pages = "307--311",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer",
number = "5",

}

Potential therapeutic targets for treatment of the overactive bladder. / Sellers, Donna J.; Christopher, R.; Chess-Williams, Chappie Russell.

In: World Journal of Urology, Vol. 19, No. 5, 2001, p. 307-311.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Potential therapeutic targets for treatment of the overactive bladder

AU - Sellers, Donna J.

AU - Christopher, R.

AU - Chess-Williams, Chappie Russell

PY - 2001

Y1 - 2001

N2 - Muscarinic receptor antagonists remain the main therapy for the treatment of the overactive bladder yet severe adverse effects make them unsuitable for a large number of patients. The development of new drugs with novel mechanisms of action for the treatment of this condition is therefore essential. This article considers some of the targets currently under investigation for the development of such compounds. jS-adrenoceptor agonists and KATP channel openers inhibit detrusor muscle activity and remain targets for drug development. There is also evidence that a-adrenoceptor antagonists may be effective in the overactive bladder, but the mechanism involved in this action is unclear. Finally the role of tachykinins in regulating bladder function through both the sensory and the motor innervation make them a potential target for drug development, but as with the the others, a selective action on the bladder must remain the goal of drug development.

AB - Muscarinic receptor antagonists remain the main therapy for the treatment of the overactive bladder yet severe adverse effects make them unsuitable for a large number of patients. The development of new drugs with novel mechanisms of action for the treatment of this condition is therefore essential. This article considers some of the targets currently under investigation for the development of such compounds. jS-adrenoceptor agonists and KATP channel openers inhibit detrusor muscle activity and remain targets for drug development. There is also evidence that a-adrenoceptor antagonists may be effective in the overactive bladder, but the mechanism involved in this action is unclear. Finally the role of tachykinins in regulating bladder function through both the sensory and the motor innervation make them a potential target for drug development, but as with the the others, a selective action on the bladder must remain the goal of drug development.

UR - http://www.scopus.com/inward/record.url?scp=0035514758&partnerID=8YFLogxK

U2 - 10.1517/14728222.8.2.95

DO - 10.1517/14728222.8.2.95

M3 - Article

VL - 19

SP - 307

EP - 311

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -